Trial intelligence / Profile preview

Post-marketing effectiveness monitoring of posaconazole injection and delayed-release tablets in Chinese patients with invasive aspergillosis

CTR20232657Phase 4Completed

Sponsor
Merck & Co.
Start
Nov 2023
Modality
Small Molecules
Countries
1
01

Overview

A Phase 4 trial of posaconazole in invasive aspergillosis (IA), sponsored by Merck & Co.. Started Nov 2023; status: completed.

02

Drugs

posaconazole
03

Conditions

invasive aspergillosis (IA)

Beyond the preview

Go deeper on CTR20232657.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20232657.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call